|
End-of-day quote
Shenzhen S.E.
2026-10-16
|
5-day change | 1st Jan Change | ||
| 3.030 CNY | -1.62% |
|
-9.55% | -5.90% |
Company Valuation: Realcan Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 7,826 | 5,881 | 6,165 | 4,920 | 4,444 | 4,779 |
| Change | - | -24.86% | 4.83% | -20.19% | -9.67% | 7.54% |
| Enterprise Value (EV) 1 | 12,117 | 5,846 | 4,743 | 6,684 | 6,040 | 5,640 |
| Change | - | -51.75% | -18.87% | 40.92% | -9.64% | -6.63% |
| P/E | 24.9x | 43.7x | -3.32x | 242x | 217x | 322x |
| PBR | 1.05x | 0.78x | 1.14x | 0.9x | 0.81x | 0.89x |
| PEG | - | -0.8x | 0x | -2x | 146.48x | -11.9x |
| Capitalization / Revenue | 0.29x | 0.28x | 0.5x | 0.61x | 0.56x | 0.66x |
| EV / Revenue | 0.45x | 0.28x | 0.39x | 0.83x | 0.76x | 0.77x |
| EV / EBITDA | 7.21x | 5.33x | 36.2x | 70x | 31.4x | 25.5x |
| EV / EBIT | 8.64x | 7.19x | -43.6x | -79.3x | 196x | 78x |
| EV / FCF | -4.62x | 1.03x | 0.99x | -1.81x | -56.6x | 5.15x |
| FCF Yield | -21.7% | 97.1% | 101% | -55.3% | -1.77% | 19.4% |
| Dividend per Share 2 | 0.018 | 0.009 | - | 0.013 | 0.011 | 0.002 |
| Rate of return | 0.34% | 0.23% | - | 0.4% | 0.37% | 0.06% |
| EPS 2 | 0.21 | 0.09 | -1.242 | 0.0135 | 0.0137 | 0.01 |
| Distribution rate | 8.57% | 10% | - | 96.3% | 80.3% | 20% |
| Net sales 1 | 27,204 | 21,060 | 12,311 | 8,034 | 7,966 | 7,296 |
| EBITDA 1 | 1,680 | 1,097 | 131.2 | 95.5 | 192.3 | 221.5 |
| EBIT 1 | 1,402 | 813.4 | -108.7 | -84.27 | 30.76 | 72.26 |
| Net income 1 | 261.3 | 131.2 | -1,832 | 20.32 | 20.62 | 16.07 |
| Net Debt 1 | 4,290 | -34.82 | -1,422 | 1,764 | 1,595 | 860.3 |
| Reference price 2 | 5.230 | 3.930 | 4.120 | 3.270 | 2.970 | 3.220 |
| Nbr of stocks (in thousands) | 1,496,437 | 1,496,437 | 1,496,437 | 1,504,710 | 1,496,437 | 1,484,264 |
| Announcement Date | 3/30/21 | 4/29/22 | 4/28/23 | 4/29/24 | 4/23/25 | 4/22/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| - | - | - | - | 666M | ||
| 35.96x | 12.96x | 27.14x | 0.55% | 1,120B | ||
| 37.4x | 6.3x | 17.74x | 2.09% | 616B | ||
| 36.43x | 8.36x | 17.24x | 2.43% | 504B | ||
| 20.46x | 4.99x | 12.38x | 2.64% | 367B | ||
| 106.52x | 5.95x | 25.12x | 2.33% | 360B | ||
| 21.18x | 5.54x | 13.63x | 2.88% | 288B | ||
| 21.7x | 4.38x | 12.55x | 2.01% | 258B | ||
| 27.46x | 7.06x | 12.64x | 2.33% | 234B | ||
| -45.63x | 6.99x | 27.07x | 2.11% | 194B | ||
| Average | 29.05x | 6.95x | 18.39x | 2.15% | 394.16B | |
| Weighted average by Cap. | 34.72x | 8.20x | 20.04x | 1.84% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002589 Stock
- Valuation Realcan Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















